GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Indivior Pharmaceuticals INDV · USD

Health Care · US listing · 🇺🇸 United States

Compare

36.28

+2.57%

Close of 2 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$1.24bn

FY2016FY2025

Net income

$210.0m

FY2016FY2025

Free cash flow

−$94.0m

FY2016FY2025

Shareholders' equity

−$98.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$1.24bn$1.19bn$1.09bn$901.0m$791.0m$647.0m$785.0m$959.9m$1.15bn$968.9m
Gross profit$993.0m$957.0m$919.0m$750.0m$664.0m$550.0m$645.0m$825.2m$1.03bn$858.1m
Research and development$97.0m$107.0m$116.0m$74.0m$52.0m$40.0m$53.0m$64.0m$93.5m$109.0m
Operating income$265.0m$32.0m−$156.0m−$79.0m$213.0m−$156.0m$178.0m$317.1m$423.3m$337.9m
Net income$210.0m$2.0m−$129.0m−$44.0m$205.0m−$148.0m$134.0m$262.7m$60.9m$32.1m
Diluted earnings per share1.680.02-0.91-0.321.46-0.960.891.750.420.22

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.20bn$1.32bn$1.76bn$1.78bn$1.83bn$1.53bn$1.65bn$1.55bn$1.44bn$1.21bn
Cash and short-term investments$195.0m$320.0m$410.0m$897.8m$1.10bn$858.0m$1.06bn$924.0m$863.0m$692.0m
Total liabilities$1.30bn$1.67bn$1.96bn$1.73bn$1.63bn$1.45bn$1.44bn$1.48bn$1.65bn$1.50bn
Debt$329.0m$333.0m$240.0m$277.0m$286.0m$285.0m$293.0m$241.0m$482.0m$535.0m
Shareholders' equity−$98.0m−$348.0m−$191.0m$51.3m$203.0m$82.0m$209.0m$66.0m−$203.0m−$295.0m
Shares outstanding125m128m142m136m140m154m151m150m144m149m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$27.0m$36.0m−$300.0m−$4.0m$353.0m−$193.0m$151.0m$303.0m$295.0m$407.0m
Capital spending−$67.0m−$31.0m−$53.0m−$5.0m−$34.0m−$4.0m−$7.0m−$41.0m−$43.0m−$35.0m
Free cash flow−$94.0m$5.0m−$353.0m−$9.0m$319.0m−$197.0m$144.0m$262.0m$252.0m$372.0m
Dividends paid—————————−$69.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$343.0m$317.0m$358.0m$314.0m$302.0m$266.0m$299.0m$307.0m
Gross profit$294.0m$277.0m$294.0m$252.0m$250.0m$222.0m$276.0m$238.0m
Operating income$160.0m$137.0m$87.0m$99.0m$72.0m$66.0m$96.0m$4.0m
Net income$122.0m$89.0m$102.0m$42.0m$18.0m$47.0m$59.0m$4.0m
Diluted earnings per share0.950.690.820.340.140.380.460.03
Cash from operations$229.0m−$9.0m−$221.0m−$39.0m$158.0m$75.0m−$5.0m$2.0m
Capital spending−$7.0m−$20.0m−$24.0m−$20.0m−$18.0m−$5.0m−$16.0m−$7.0m
Free cash flow$222.0m−$29.0m−$245.0m−$59.0m$140.0m$70.0m−$21.0m−$5.0m
Total assets$1.23bn$1.20bn$1.20bn$1.42bn$1.45bn$1.38bn$1.32bn$1.46bn
Cash and short-term investments$222.0m$175.0m$195.0m$445.0m$510.0m$373.0m$320.0m$318.0m
Debt$496.0m$495.0m$329.0m$332.0m$337.0m$340.0m$343.0m$249.0m
Shareholders' equity−$208.0m−$144.0m−$98.0m−$207.0m−$258.0m−$286.0m−$348.0m−$167.0m

Financial ratios

Data as of 18 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin80.1%80.6%84.1%83.2%83.9%85.0%
Operating margin22.9%4.6%-10.4%-6.9%27.3%-23.0%
Net margin16.9%0.2%-11.8%-4.9%25.9%-22.9%
Return on equity-214.3%-0.6%67.5%-85.8%101.0%-180.5%
Return on assets17.4%0.2%-7.3%-2.5%11.2%-9.7%
Free cash flow yield1.0%1.6%-5.4%0.0%8.5%-3.8%
Revenue growth4.3%8.7%21.3%13.9%22.3%-17.6%
Earnings growth10400.0%-101.6%193.2%-121.5%-238.5%-210.4%
Current ratio0.71x0.89x0.98x1.24x1.80x1.98x
Debt to equity-3.36x-0.99x-1.30x4.84x1.23x2.95x
Equity ratio-8.1%-26.4%-10.8%2.9%11.1%5.4%
Interest coverage6.31x1.34x-3.26x-2.14x8.31x-6.21x
R&D as a share of sales7.8%9.0%10.6%8.2%6.6%6.2%
Buybacks as a share of market value2.4%9.8%-4.0%2.9%8.8%-2.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.2%13.9%2.0%
Operating income——-2.6%
Net income——-0.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin80.3%81.9%82.5%84.8%
Operating margin12.2%1.4%2.0%16.0%
Net margin8.7%0.9%1.6%7.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings21.4—-16.8-67.511.8-7.62.91.514.919.0
Price to sales3.61.32.03.33.11.70.50.40.80.6

Market value over time

30 Nov 2016 to 16 Oct 2026, in USD

$607.9m$4.19bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return209%-24%-31%35%162%145%-9%-55%52%35%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 3 Nov 2026.

FY2026FY2016FY2015
Paid in the year8.130.3650.116
  • 5-to-1 reverse split · 11 Oct 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.